A Phase 2 interventional study of Halneuron and Placebo in Chemotherapy Induced Neuropathic Pain, Chemotherapy Induced Pain Neuropathy and Chemotherapy Induced Pain, sponsored by Dogwood Therapeutics Inc.. Active, not recruiting at 25 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Dogwood Therapeutics Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 291 studies in Neuralgia with a site in United States — 50 open to participants now, 61 under way, 5 of them phase 3. Neuralgia · United States.
Among the 291 studies in Neuralgia with a site in United States, this one is the 29th largest by planned enrollment of the 261 interventional ones that give a count, is one of 13 that started in 2025, is one of 78 in phase 2, reaches primary completion later than 13 of the 60 other live ones, and was the 267th registered.
1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.
Browse Neuralgia studies →50 of the 291 studies in Neuralgia with a site in United States are open now. Recruiting first, the newest first:
University of Miami · Sites in United States
Ages 50+
James J. Peters Veterans Affairs Medical Center · Sites in United States
Ages 22+
EicOsis Human Health Inc. · Sites in United States
Ages 18+
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
Eli Lilly and Company · Sites in United States, Puerto Rico
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 153 Neuralgia studies recruiting now, 77 (50%) set no upper age limit and 44 (29%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
291 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 32 · Phase 2 94 · Phase 3 26 · Phase 4 14
First in 1993; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 52 across 832 interventional studies indexed under Neuralgia.
Median enrollment 40 across the 261 interventional studies, 53 across the 28 observational. Of the 193 that completed or were terminated, 86 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
105 of 291 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Dogwood Therapeutics Inc. as lead sponsor.
Dogwood Therapeutics Inc. has 1 study filed under Neuralgia — fewer than ten, so there is no comparison to draw.
27 of the studies in Neuralgia with a site in United States that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06696443Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) | 2027-01-25 |
| NCT07231419Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy | 2027-04-06 |
| NCT06628908Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy | 2027-05-31 |
| NCT06848348Dogwood Therapeutics Inc.Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain | 2026-12 |
| NCT04865679Axogen CorporationTolerability and Feasibility Pilot Clinical Study of a Large-Diameter Nerve Cap for Protecting and Preserving Terminated Nerve Ends | 2026-12 |
Add all 27 to your calendar (.ics) → With an account.
Among the 291 studies in Neuralgia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A randomized study to determine safety and efficacy of a series of subcutaneous (SC) injections of HAL in patients with CINP, compared to matching placebo injections. After that, subjects may have the option to enter an Open Label extension phase, where available, in which all subjects will receive Halneuron.
1,102 studies on the registry are indexed under Neuralgia; 242 are open to participants now.
This study's planned enrollment of 240 is above the median of 52 across 832 interventional studies indexed under Neuralgia.
Browse Neuralgia studies →This is the only study on the registry with Dogwood Therapeutics Inc. as lead sponsor.
Compared within Neuralgia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Placebo
Drug: Placebo
Halneuron
Drug: Halneuron
Subjects may choose to continue in an Open Label Extension (OLE) phase if they complete the randomized phase. All subjects regardless of treatment assignment in the randomized phase will receive Halneuron, during the OLE phase of the study, if offered by the clinical site.
Drug: Halneuron · Drug: Halneuron (Open Label Extension)
Halneuron for Subcutaneous Injection
Placebo for Subcutaneous Injection
Halneuron for Subcutaneous Injection
NRS Pain
Change from Baseline in the weekly average of daily 24-hour pain intensity scores analyzed by percentage of responders among patients treated with Halneuron compared to Placebo
Time frame: From enrollment to end of study at 4 weeks
Safety Assessments
Incidence of serious adverse events (SAEs), adverse events (AEs) and Adverse Events of Special Interests (AESIs)
Time frame: From enrollment to end of study at 4 weeks
Patient Global Impression of Change (PGIC)
Patient Global Impression of Change (PGIC)
Time frame: Enrollment to end of study at week 4
PROMIS Fatigue
Change from baseline to week 4 on the PROMIS Fatigue instrument
Time frame: Enrollment to end of study at week 4
PROMIS Sleep
Change from baseline to week 4 on PROMIS Sleep instrument
Time frame: Enrollment to end of study at week 4
PROMIS-29 Quality of Life
Change from baseline to week 4 on the domains of the PROMIS-29 instrument
Time frame: Enrollment to end of study at week 4
Plan to share: Yes
Supporting information: Clinical study report
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.
Of 34 industry-sponsored phase 2 interventional studies under Neuralgia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 22. This study's planned 22 months is above that.
Counting every sponsor, half of 58 studies reached it within 22 months; a quarter within 11 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tetrodotoxin